A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Although fasiglifam significantly improved glycemic contro...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/875ecff2c84d4653af7caf3a7d844768 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:875ecff2c84d4653af7caf3a7d844768 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:875ecff2c84d4653af7caf3a7d8447682021-11-18T08:51:39ZA novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.1932-620310.1371/journal.pone.0076280https://doaj.org/article/875ecff2c84d4653af7caf3a7d8447682013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24130766/?tool=EBIhttps://doaj.org/toc/1932-6203Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Although fasiglifam significantly improved glycemic control in type 2 diabetes patients with a minimum risk of hypoglycemia in a phase 2 study, the precise mechanisms of its potent pharmacological effects are not fully understood. Here we demonstrate that fasiglifam acts as an ago-allosteric modulator with a partial agonistic activity for FFAR1. In both Ca(2+) influx and insulin secretion assays using cell lines and mouse islets, fasiglifam showed positive cooperativity with the FFAR1 ligand γ-linolenic acid (γ-LA). Augmentation of glucose-induced insulin secretion by fasiglifam, γ-LA, or their combination was completely abolished in pancreatic islets of FFAR1-knockout mice. In diabetic rats, the insulinotropic effect of fasiglifam was suppressed by pharmacological reduction of plasma free fatty acid (FFA) levels using a lipolysis inhibitor, suggesting that fasiglifam potentiates insulin release in conjunction with plasma FFAs in vivo. Point mutations of FFAR1 differentially affected Ca(2+) influx activities of fasiglifam and γ-LA, further indicating that these agonists may bind to distinct binding sites. Our results strongly suggest that fasiglifam is an ago-allosteric modulator of FFAR1 that exerts its effects by acting cooperatively with endogenous plasma FFAs in human patients as well as diabetic animals. These findings contribute to our understanding of fasiglifam as an attractive antidiabetic drug with a novel mechanism of action.Chiori YabukiHidetoshi KomatsuYoshiyuki TsujihataRisa MaedaRyo ItoKae Matsuda-NagasumiKensuke SakumaKazumasa MiyawakiNaoya KikuchiKoji TakeuchiYugo HabataMasaaki MoriPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 10, p e76280 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Chiori Yabuki Hidetoshi Komatsu Yoshiyuki Tsujihata Risa Maeda Ryo Ito Kae Matsuda-Nagasumi Kensuke Sakuma Kazumasa Miyawaki Naoya Kikuchi Koji Takeuchi Yugo Habata Masaaki Mori A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. |
| description |
Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Although fasiglifam significantly improved glycemic control in type 2 diabetes patients with a minimum risk of hypoglycemia in a phase 2 study, the precise mechanisms of its potent pharmacological effects are not fully understood. Here we demonstrate that fasiglifam acts as an ago-allosteric modulator with a partial agonistic activity for FFAR1. In both Ca(2+) influx and insulin secretion assays using cell lines and mouse islets, fasiglifam showed positive cooperativity with the FFAR1 ligand γ-linolenic acid (γ-LA). Augmentation of glucose-induced insulin secretion by fasiglifam, γ-LA, or their combination was completely abolished in pancreatic islets of FFAR1-knockout mice. In diabetic rats, the insulinotropic effect of fasiglifam was suppressed by pharmacological reduction of plasma free fatty acid (FFA) levels using a lipolysis inhibitor, suggesting that fasiglifam potentiates insulin release in conjunction with plasma FFAs in vivo. Point mutations of FFAR1 differentially affected Ca(2+) influx activities of fasiglifam and γ-LA, further indicating that these agonists may bind to distinct binding sites. Our results strongly suggest that fasiglifam is an ago-allosteric modulator of FFAR1 that exerts its effects by acting cooperatively with endogenous plasma FFAs in human patients as well as diabetic animals. These findings contribute to our understanding of fasiglifam as an attractive antidiabetic drug with a novel mechanism of action. |
| format |
article |
| author |
Chiori Yabuki Hidetoshi Komatsu Yoshiyuki Tsujihata Risa Maeda Ryo Ito Kae Matsuda-Nagasumi Kensuke Sakuma Kazumasa Miyawaki Naoya Kikuchi Koji Takeuchi Yugo Habata Masaaki Mori |
| author_facet |
Chiori Yabuki Hidetoshi Komatsu Yoshiyuki Tsujihata Risa Maeda Ryo Ito Kae Matsuda-Nagasumi Kensuke Sakuma Kazumasa Miyawaki Naoya Kikuchi Koji Takeuchi Yugo Habata Masaaki Mori |
| author_sort |
Chiori Yabuki |
| title |
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. |
| title_short |
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. |
| title_full |
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. |
| title_fullStr |
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. |
| title_full_unstemmed |
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. |
| title_sort |
novel antidiabetic drug, fasiglifam/tak-875, acts as an ago-allosteric modulator of ffar1. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/875ecff2c84d4653af7caf3a7d844768 |
| work_keys_str_mv |
AT chioriyabuki anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT hidetoshikomatsu anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT yoshiyukitsujihata anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT risamaeda anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT ryoito anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kaematsudanagasumi anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kensukesakuma anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kazumasamiyawaki anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT naoyakikuchi anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kojitakeuchi anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT yugohabata anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT masaakimori anovelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT chioriyabuki novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT hidetoshikomatsu novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT yoshiyukitsujihata novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT risamaeda novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT ryoito novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kaematsudanagasumi novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kensukesakuma novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kazumasamiyawaki novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT naoyakikuchi novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT kojitakeuchi novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT yugohabata novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 AT masaakimori novelantidiabeticdrugfasiglifamtak875actsasanagoallostericmodulatorofffar1 |
| _version_ |
1718421213874749440 |